Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Head and Neck Neoplasms 4Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Medulloblastoma 2Fallopian Tube Neoplasms 2Tonsillar Neoplasms 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Prostatic Neoplasms 1Pinealoma 1Pharyngeal Neoplasms 1Pelvic Neoplasms 1Pancreatic Adenocarcinoma 1Ototoxicity 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Muscle Invasive Bladder Urothelial Carcinoma 1Mesothelioma, Malignant 1Lymphoma, B-Cell 1Liposarcoma 1Hepatoblastoma 1Esophageal Squamous Cell Carcinoma 1EGFR Positive Non-small Cell Lung Cancer 1Desmoplastic Small Round Cell Tumor 1Colonic Neoplasms 1

Interventions

Interleukin 1 Receptor Antagonist Protein 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Pancreatic Adenocarcinoma × Cisplatin × Clear all
NCT02550327 2021-06-22

Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer

Baylor Research Institute

Phase EARLY_PHASE1 Completed
20 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡